Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRACTION-Gastric Cancer phase 2 study of nivolumab-based immuno-oncology combinations in advanced gastric cancer
MOH_2017-05-15_000365Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastric cancer (GC) comparing Opdivo + Yervoy, Opdivo + BMS-986016 and Opdivo + BMS-986205 (3 arms). Started Mar 2017; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on MOH_2017-05-15_000365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-15_000365.